The Retatrutide 40mg Injection Pen is a cutting-edge peptide delivery system designed for adults seeking effective weight management and glycemic control. As a novel triple-agonist, it uniquely activates GLP-1, GIP, and glucagon receptors simultaneously, offering a multi-dimensional approach to metabolic regulation . This mechanism enhances insulin secretion, suppresses appetite, boosts energy expenditure, and promotes lipolysis, delivering comprehensive benefits beyond traditional single-target therapies.
Each pre-filled pen contains 40mg of high-purity retatrutide, engineered for convenient weekly subcutaneous injection. The user-friendly design allows easy dose adjustment, with a gradual escalation schedule recommended—starting from lower doses to maximize tolerability before reaching optimal levels . Clinical trials confirm its efficacy: patients on retatrutide doses ≥4mg achieved significant weight loss (up to 24% of body weight at 48 weeks) and meaningful reductions in HbA1c and fasting glucose .
Ideal for individuals with obesity (BMI ≥27) or type 2 diabetes, the pen ensures consistent dosing and stability when stored at 2–8°C . Common side effects are mild gastrointestinal issues, often mitigated by gradual dose titration . With its sterile, ready-to-use format and proven therapeutic profile, this injection pen provides a reliable solution for long-term metabolic health management.
Wan Chai District, Hong Kong, China
